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OBJECTIVE — Cardiomyopathyisnotedinupto40%ofinfantsofdiabeticmothers,andthe
exact mechanisms are unknown. The aim of this study was to determine whether fetal serum
markers of cardiac function differ between normal and type 1 diabetic pregnancies and to
examine the relationship between these markers and fetal cardiac structure and function.
RESEARCH DESIGN AND METHODS — This was a prospective observational study
of45type1diabeticpregnanciesand39normalpregnancies.Allparticipantshadconcentrations
of fetal pro–B-type natriuretic peptide (proBNP) and troponin-T (TnT) measured at the time of
delivery.Allpatientswithtype1diabeteshadDopplerevaluationoftheumbilicalartery,middle
cerebralartery,andductusvenosusinthethirdtrimester,andasubset(n21)haddetailedfetal
echocardiograms performed in each trimester.
RESULTS — FetalproBNPandTnTconcentrationswerehigherinthediabeticcohortthanin
the normal cohort (P  0.05). ProBNP correlated positively with interventricular septum thick-
ness(P0.05)butnotwithcardiacfunctionindexesinthethirdtrimester.Inpatientswithpoor
glycemic control, there was a signiﬁcant positive correlation (P  0.05) between fetal TnT and
thethirdtrimesterumbilicalarterypulsatilityindex.TherewerealsoincreasedlevelsoffetalTnT
in infants with poor perinatal outcome (P  0.05).
CONCLUSIONS — Biochemical markers of cardiac dysfunction are elevated in infants of
diabetic mothers, especially those with cardiomyopathy or poor perinatal outcome. Hypergly-
cemiainearlypregnancymayaffectmyocardialandplacentaldevelopment,thuscontributingto
the susceptibility to hypoxia seen in these infants.
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P
regestational insulin-dependant di-
abetes (type 1 diabetes) is a rela-
tively common condition in
pregnancy, affecting up to 0.5% of the
pregnant population (1). Fetuses of dia-
beticmothersareatincreasedriskofperi-
natal morbidity and mortality (2,3). A
well-recognized complication of diabetic
pregnancy is the condition of hypertro-
phic cardiomyopathy, which is found in
40% of infants born to diabetic mothers
and causes symptoms in 5% (3,4).
Whereas diabetic cardiomyopathy is of-
ten transient with no lasting conse-
quences for the majority of infants,
impaired cardiac function leading to con-
gestive cardiac failure has been reported
in some infants of mothers with poorly
controlled diabetes (5). In addition there
are case reports of fetal death due to hy-
pertrophic cardiomyopathy (6). Our
group has reported previously that still-
born infants of diabetic mothers have
heavier hearts than stillborn infants of
nondiabetic mothers after correction for
fetalsize,suggestingthatcardiomyopathy
may have a role in “unexplained” fetal
death in diabetic pregnancy (7). The eti-
ology of this cardiomyopathy is poorly
understood with proposed mechanisms
including fetal hyperglycemia, hyperin-
sulinemia,andchronichypoxia(8).More
recentlyourgrouphassuggestedthatcar-
diomyopathy occurs in response to func-
tional changes evident in the ﬁrst
trimester in fetuses of pregestational type
1 diabetic mothers (9).
Troponin is an inhibitory protein
complex found in all striated muscle, and
the cardiac-speciﬁc isoform troponin T
(TnT) is a sensitive and speciﬁc marker of
myocardialischemia.TheTnTconcentra-
tion in cord blood is unaffected by gesta-
tion, birth weight, sex, or mode of
delivery (10). Newborns with intrapar-
tum asphyxia have increased plasma
troponin I and TnT concentrations, sug-
gesting that the fetal heart is sensitive to
acute hypoxia (11,12). TnT levels are sig-
niﬁcantly higher in sick neonates who
subsequently develop respiratory distress
compared with healthy neonates, sug-
gesting that cardiorespiratory compro-
mise in the neonate may be assessed by
this biochemical marker (13).
B-type natriuretic peptide (BNP) is a
32–amino acid peptide released by ven-
tricular cardiac myocytes in response to
cardiac volume and pressure overload. It
exerts a vasodilatatory and natriuretic ef-
fectandisincreasedinpatientswithheart
failure, including those with hypertro-
phic and dilated cardiomyopathy (14). It
is initially released as an inactive prohor-
mone (proBNP) that appears to be a sen-
sitive marker for acute cardiac stress (15).
Natriuretic peptides also appear to have a
roleinregulatingcardiacgrowthandmay
have a cardioprotective role in preventing
cardiomyopathy as mice lacking BNP or
BNP receptor genes display cardiac ﬁbro-
sis and hypertrophy (16).
Pregestational type 1 diabetes in the
pregnant mother is strongly associated
with neonatal cardiomyopathy (odds ra-
tio 15.1 [95% CI 5.5–41.3]) (17). How-
ever, there is a paucity of data in the
literature on biochemical assessment of
fetal cardiac function in pregestational
type 1 diabetic pregnancy. There are only
two studies in the literature on fetal
proBNP in pregestational type 1 diabetic
pregnancy(18,19)andnoneonfetalTnT.
The primary aim of this study was to as-
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sessed by cord blood TnT and proBNP
levels, differs between normal and type 1
diabetic pregnancy. A secondary aim was
to determine whether there is a relation-
ship between these biochemical cardiac
markers and glycemic control, fetal car-
diac function or structure, placental he-
modynamics, or perinatal outcome.
RESEARCH DESIGN AND
METHODS— A total of 45 pregesta-
tional type 1 diabetic pregnant women
and 39 normal nondiabetic pregnant
women were included in this prospective
observational study. Patients gave in-
formed written consent, and institutional
ethics approval was obtained. The Na-
tional Maternity Hospital has an annual
deliveryrateof9,000birthsperannum.
The control group consisted of 39 neo-
nates born after uncomplicated pregnan-
cies with no evidence of impaired glucose
tolerance. None of these women had gly-
cosuria during their pregnancy or any
other indication for formal glucose toler-
ance testing. A random serum glucose
measurement was obtained at the time of
recruitmenttothestudy,andthiswas7
mmol/l for all control subjects.
This center provides care for 35–40
pregestationaltype1diabeticmothersan-
nually. Patients attend a dedicated multi-
disciplinaryclinicstaffedbyobstetricians,
diabetologists, dietitians, and a midwife
specializing in diabetic pregnancies. The
ﬁrst visit in early pregnancy is at 6
weeks,andpatientsareusuallyseenevery
2 weeks thereafter. The mean  SD dura-
tion of diabetes in the diabetic cohort was
16.5  8.7 years. With regard to white
class, there were 16 B, 5 C, 15 D, 6 R, and
3 R/F. Eleven women (24%) of our pop-
ulation had vasculopathy, deﬁned as
white class R, F, R/F, or the presence of
prepregnancy hypertension. Twenty-
seven women (60%) delivered a macro-
somic infant, deﬁned as birth weight
greater than the 90th centile for gesta-
tional age and sex based on growth charts
(Child Growth Foundation, London,
1996) used in this institution (20). None
of the diabetic cohort were smokers; un-
fortunately, accurate smoking data were
not available for the normal cohort.
Glycemic control
Early pregnancy good glycemic control is
deﬁned as an A1C value of 7% at the
ﬁrst visit to the multidisciplinary diabetes
clinic. Glycemic control is monitored
eight times daily by patients, and patients
phone in their results twice per week for
advice on insulin dose alteration. Values
for fasting and postprandial glucose are
consideredabnormaliftheyare5and7
mmol/l, respectively. First, second, and
third trimester good glycemic control is
deﬁned as an A1C value less than the me-
dian for the cohort in that trimester, i.e.,
ﬁrst 6.6%, second 6.2%, and third
A1C 6.3% (Table 1).
Ultrasonographic measurements
All patients in the diabetic cohort (n 
45) had cord blood sampling and Dopp-
ler ultrasonographic evaluation of the
umbilical artery, middle cerebral artery,
and ductus venosus circulation in the
third trimester. A subset of fetuses in the
diabeticcohort(n21)underwentafetal
cardiac echocardiogram to assess cardiac
function and structure in each trimester.
The fetal echocardiograms were per-
formed at 12–14 weeks (ﬁrst trimester),
20–22 weeks (second trimester), and
34–36 weeks (third trimester) gestation
by a trained research fellow and a mater-
nal fetal medicine specialist as described
previously (9).
Cardiac function
Cardiac function was assessed in each tri-
mester. In brief, systolic function was
measuredbyassessingisovolumetriccon-
traction time and diastolic function was
measured by assessing the isovolumetric
relaxationtimeandtheratiobetweenpas-
sive and active ventricular ﬁlling in both
ventricles.Globalcardiacfunctionwasas-
sessed by measuring the myocardial per-
formance index in both ventricles.
Cardiac structure
Cardiac structure was assessed in the sec-
ond and third trimester because the small
size of the 14-week fetal heart precluded
measurement in the ﬁrst trimester. The
interventricularseptum(IVS)andleftand
rightventricularfreewallsweremeasured
as described previously (9).
Table 1—Descriptive data of normal and pregestational diabetic cohorts
Normal
Type 1
diabetes P
n 39 45
Maternal age (years) 32  53 2  4N S
Parity 1 (0–4) 1 (0–3) NS
BMI (kg/m
2) 22.97  3.57 26.13  4.34 0.001
Duration type 1 diabetes (years) N/A 16 (1–32)
Vasculopathy N/A 11 (24%)
TnT (ng/ml) 0.00 (0–0.02) 0.02 (0–0.05) 0.006
ProBNP (pmol/l) 86 (6–166) 126 (0–254) 0.015
Early pregnancy A1C (%) N/A 7.5  1.5
14/40 A1C (%) N/A 6.6  0.9
20/40 A1C (%) N/A 6.2  0.8
36/40 A1C (%) N/A 6.3  0.8
Birth weight(g) 3,568  486 3,805  416 0.018
Birth weight centile 59.3  30.5 84.4  17.8 0.000
Macrosomia 12 (31%) 27 (60%) 0.008
Gestational age at delivery (weeks) 39  13 8  1 0.000
Mode of delivery
Planned CS 20 (59%) 21 (47%) NS
Emergency CS 7 (18%) 11 (24%) NS
Vaginal delivery 12 (31%) 13 (29%) NS
Apgar score at 1 min 9 9 NS
Apgar score at 5 min 9 9 NS
Cord pH arterial 7.29  0.04 7.25  0.08 0.016
Venous 7.35  0.04 7.30  0.09 0.017
Infants born with pH 7.2 0 (0%) 10 (25%) 0.007
Admission to NICU 1 (2.6%) 24 (53%) 0.000
Poor perinatal outcome 1 (2.6%) 17 (38%) 0.000
Data are means  SD, median (range), median (interquartile range), n (%), or median. Vasculopathy: white
class R, F, R/F, or the presence of pre pregnancy hypertension; early pregnancy A1C: A1C at gestational age
73weeks;CS,cesareansection;Macrosomiaisbirthweightgreaterthanthe90thcentileforgestationalage
and sex based on growth charts (Child Growth Foundation, London, 1996).
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Inthethirdtrimestertheumbilicalartery,
middle cerebral artery, and ductus veno-
sus were examined. Fetal cardiac after-
load was assessed by obtaining the
pulsatility index of the umbilical artery.
Cardiacpreloadwasassessedbymeasure-
ment of the pulsatility index for the duc-
tusvenosus.Theredistributionofthefetal
arterial circulation was assessed by mea-
surement of the pulsatility index of the
middle cerebral artery.
Perinatal outcome
A composite “poor perinatal outcome” cat-
egory was used to divide the type 1 preges-
tational diabetic cohort into good and poor
perinatal outcome. Poor perinatal outcome
was deﬁned as one of the following: admis-
sion to a neonatal intensive care unit
(NICU) for a reason other than hypoglyce-
mia  requirement of artiﬁcial ventilation;
arterialcordpH7.2;Apgarscoreat1min
3;Apgarscoreat5min7;ordeliveryat
37 weeks. The latter category was in-
cluded as the four deliveries before 37
weeksinthediabeticpopulationwerefeltto
be related to maternal diabetes: polyhy-
dramnios leading to premature labor (n 
2), poor glycemic control and macrosomia
(n  1); and preterm prelabor rupture of
membranes with emergency caesarean be-
cause of meconium grade 2 (n  1).
Biochemical markers
Umbilical blood samples were collected
immediately after delivery in serum tubes
and centrifuged at 4°C. Serum samples
were stored at 20°C until analysis using
the Elecsys 2010 (Roche Diagnostics).
Plasma proBNP levels were measured via
a noncompetitive chemiluminescent as-
say. The variance was 4.6% (5.6 pmol/l)
and1.9%(107.5pmol/l),respectively,for
low-andhigh-concentrationpatientsam-
ples, and the respective day-to-day vari-
ance was 5.5% (6.4 pmol/l) and 2.6%
(113.6 pmol/l). TnT levels were deter-
mined by an electrochemiluminescent
sandwich enzyme-linked immunoassay.
Theminimaldetectionlimitwas0.01g/l
with minimal cross-reactivity with car-
diactroponinI(0.002%)andskeletaltro-
ponin T (0.001%). The repeatability
coefﬁcient for a paired sample was 10%,
and the variability coefﬁcient for preci-
sion analysis was 6.4%.
Statistical analysis
Statistical analysis was performed with
SPSS (version 12). Descriptive statistics
and plots were obtained to examine the
data and determine distribution, skew-
ness,kurtosis,andoutliers.Values5in-
terquartile ranges from the median were
excluded from further analysis, leading to
the exclusion of three proBNP values and
one TnT value.
Statistical analysis was performed by
ANOVA when the data were normally
distributed with post hoc Bonferroni
analysis. Comparisons were made be-
tween the two cohorts using the nonpara-
metric Mann-Whitney U test if the data
were not normally distributed and Stu-
dent t test if data were normally distrib-
uted. Categorical data were compared
using a 
2 test. A Nonparametric Spear-
man 	 test and linear regression analysis
were used to investigate the relationship
between proBNP and TnT and cardiac
function and structure parameters and
Doppler indexes. P  0.05 was consid-
ered statistically signiﬁcant.
RESULTS
Normal versus diabetic populations
The demographic data of the normal and
diabetic populations are summarized in
Table 1. The neonates born to pregesta-
tional diabetic mothers were delivered
earlier (P  0.001) with a higher birth
weight (P  0.05) compared with the
control group. There were no differences
betweenthecohortswithrespecttomode
of delivery or Apgar score at 1 min or at 5
min, but neonates of diabetic mothers
weresigniﬁcantlymorelikelytobeadmit-
ted to the NICU (P  0.001). Only one of
the normal cohort was classiﬁed as poor
perinatal outcome after spontaneous vag-
inal delivery with good outcome at 36
weeks. Ten of the diabetic cohort and
none of the normal cohort had an arterial
pH 7.2. Fetal cord blood proBNP and
TnT levels were higher in the diabetic co-
hort (P  0.05), and proBNP correlated
positively with TnT (P  0.0001). Nei-
ther TnT nor proBNP levels correlated
with birth weight centile, gestational age
at delivery, or mode of delivery.
Glycemic control
Compared with the normal mothers, pre-
gestational diabetic mothers with good
control in early pregnancy had increased
cord blood levels of TnT (0.02  0.04 vs.
0.00  0.02, P  0.05) and similar levels
of proBNP (123  137 vs. 86  80, NS),
whereas diabetic mothers with poor con-
trol had signiﬁcantly increased cord
blood levels of both TnT and proBNP
(0.02  0.07 and 141  78, respec-
tively). There was no association between
proBNP or TnT and ﬁrst, second, or third
trimester maternal glycemic control.
Fetal echocardiography
Cardiac structure. When we divided
our diabetic cohort into those with a nor-
mal third trimester IVS versus those with
a thickened IVS (deﬁned as IVS 6.39
mm, the mean for the diabetic cohort) we
found signiﬁcantly higher levels of
proBNP in those with septal hypertrophy
(185  103 vs. 72  54, P  0.008; n 
11 vs. n  10) (Fig. 1A). There was a
Figure 1—A: Relationship between third trimester (T3) IVS thickness and fetal proBNP. Equation: y  49.884x  191.1; R
2  0.4753. B:
Relationship between third trimester UAPI and TnT in pregnant women with poorly controlled type 1 diabetes. Poorly controlled type 1 diabetes is
deﬁned as early pregnancy A1C 7% at mean  SD gestational age of 7  3 weeks. Equation: y  0.0638x  0.0333; R
2  0.1418.
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proBNP and third trimester IVS thickness
in both systole and in diastole (r coefﬁ-
cient 0.489, P  0.05). There was no sig-
niﬁcant correlation between TnT levels
and third trimester cardiac structure.
There was no relationship between fetal
TnT or proBNP levels and second trimes-
ter cardiac structure.
Cardiac function. There was no signiﬁ-
cant correlation with cord blood proBNP
or TnT and fetal cardiac function in the
ﬁrst,second,orthirdtrimesters(Table2).
Doppler indexes
When all diabetic patients were included
there was a nonsigniﬁcant trend toward a
positive correlation between TnT and
umbilical artery pulsatility index (UAPI)
with increased levels of TnT found when
UAPI increased (P  0.065). The median
A1C in the diabetic cohort in the third
trimester was 6.3%. Among patients with
third trimester A1C 6.3%, a signiﬁcant
correlation was noted between TnT and
UAPI (r coefﬁcient 0.436, P  0.05) (Fig.
1B). There was no association between
TnTandmiddlecerebralarterypulsatility
indexorductusvenosuspulsatilityindex.
There was no correlation between
proBNP and umbilical artery, middle ce-
rebral artery, or ductus venosus Doppler
indexes.
Perinatal outcome
Only one infant had clinically recognized
cardiomyopathy with fetal proBNP mea-
suring 7,092 pmol/l and TnT measuring
0.07 ng/ml. This diabetic mother pre-
sented for assessment at 38 weeks com-
plaining of a 24 history of decreased fetal
movements. An emergency cesarean sec-
tion was performed because of a patho-
logical cardiotocograph, and her infant
had an Apgar score of 1 at 1 min and 7 at
5 min with an arterial pH of 7.07. The
infant was transferred to the NICU and
made a good recovery with expectant
management. The initial neonatal echo-
cardiogramshowedsigniﬁcantcardiomy-
opathy, which had resolved completely
by the follow-up echocardiogram at day
56 of postnatal age.
Among diabetic pregnancies, there
was no signiﬁcant difference between
proBNP or TnT levels in those infants
who were admitted to the NICU versus
those who were not. However, within the
diabetic group fetal TnT was signiﬁcantly
elevated in those infants with poor peri-
natal outcome (17 poor vs. 27 good, me-
dian0.04[interquartilerange0–0.11]vs.
0.02 [0–0.02] ng/ml, P  0.05). There
was no difference in fetal proBNP levels
(poor outcome n  14, 181 [0–378]
pmol/l vs. good outcome n  28, 123
[49–197] pmol/l; NS). Whereas no rela-
tionship was found in the total group be-
tween mode of delivery and TnT or
proBNP, within the diabetic cohort in-
creased levels of TnT were noted in in-
fantsdeliveredbyemergencyintrapartum
cesarean section or instrumental delivery
forfetaldistress/failuretoadvancecom-
pared with those delivered by planned
cesarean or spontaneous vaginal deliv-
ery (0.03  0.11 vs. 0.00  0.02; P 
0.05). There was no difference in
proBNP levels between these groups.
Overall there was no correlation be-
tween arterial cord pH and fetal TnT or
proBNPinthetotalgroup.Inparticular,
among fetuses of diabetic pregnancy
alone, the mean  SD cord TnT value
with cord pH 7.2 was 0.03  0.03 vs.
0.03  0.03 and with cord pH 7.2
was 0.027  0.03 (NS).
CONCLUSIONS — Fetal proBNP and
TnT concentrations are higher in fetuses
of diabetic mothers than in the normal
population. Third trimester interventric-
ular septal thickening correlates with lev-
els of fetal proBNP. In pregnant women
with poorly controlled diabetes, abnor-
mal third trimester umbilical artery
Doppler index is associated with in-
creased cord blood TnT. In addition, fe-
tuses of diabetic mothers with poor
perinatal outcome have higher levels of
cord blood TnT.
Neither proBNP nor TnT concentra-
tions in total were signiﬁcantly associated
with mode of delivery, gestational age at
delivery, or birth weight, consistent with
previous studies (10,18). No relationship
was noted between proBNP and Tropo-
nin-Tandthirdtrimestercardiacfunction
parameters in the diabetic cohort. We
have previously described normal cardiac
function in this group (9), but the ﬁnd-
ings in this article suggest that biochemi-
cal markers are more sensitive than
ultrasonographic measurements in the
detection of cardiac dysfunction.
The strengths of this article are that it
provides new data on the relationship be-
tween fetal TnT and proBNP with cardiac
function and structure, glycemic control,
fetalandplacentalDopplerdata,andperi-
natal outcome. Ideally all of the normal
cohort would have had an oral glucose
challenge test to exclude gestational dia-
betes. However, none of our patients had
a predelivery random glucose value 7
mmol/l, a personal or family history of
diabetes, or other risk factors for gesta-
tional diabetes. Another potential limita-
tion is the timing of the third trimester
assessmentofcardiacfunction.Itwasper-
formed at 36 weeks, whereas the mean
ageatdeliverywas38weeks.Afetalecho-
cardiogram closer to delivery may have
shown better correlation between bio-
chemical and echocardiographic markers
of cardiac function.
Table 2—Effect of advancing gestational age on cardiac function and structural indexes and
Doppler indexes in type 1 diabetic pregnancy
First
trimester
Second
trimester
Third
trimester
Function
Left E/A ratio 0.55  0.05 0.62  0.07 0.84  0.15
Left IVRT (m/s) 46  10 43  95 1  7
Left ICT (m/s) 38  11 36  10 34  10
Left MPI 0.57  0.14 0.51  0.11 0.57  0.10
Right E/A ratio 0.61  0.07 0.64  0.07 0.90  0.32
Right MPI 0.54  0.12 0.53  0.16 0.53  0.13
Structure
IVS systole (mm) N/A 3.24  0.79 6.39  1.42
IVS diastole (mm) N/A 2.42  0.55 5.30  1.32
Right FW (mm) N/A 1.74  0.44 3.17  0.77
Left FW (mm) N/A 1.67  0.42 3.15  0.70
UAPI 1.56  0.45 1.19  0.21 0.88  0.18
MCAPI N/A 1.55  0.30 1.58  0.34
DVPI 0.92  0.44 0.76  0.37 0.54  0.24
Data are means SD. DVPI, ductus venosus pulsatility index; E/A ratio, ratio of passive-to-active ventricular
ﬁlling; FW, free wall of ventricle; ICT, isovolumetric contraction time; IVRT, isovolumetric relaxation time;
MCAPI: middle cerebral artery pulsatility index; MPI, myocardial performance index; N/A, not applicable.
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pregnancies have been reported previ-
ously (18,19), but we are the ﬁrst to
demonstrate a relationship with interven-
tricular septal thickening. We have also
explored this relationship further by cor-
relationwithfetalcirculationanddetailed
echocardiography data. In response to a
mild degree of cardiac failure, it is possi-
ble that in the fetus proBNP is released to
prevent signiﬁcant cardiac hypertrophy.
Similartoourgroup(21),Halseetal.(18)
found increased proBNP in diabetic preg-
nancies,whichwassigniﬁcantlyhigherin
patients with poor glycemic control. Lo-
calreleaseofBNPactsasavasodilatorata
placental level (22), thus lowering fetal
afterload and preventing cardiomyopa-
thy. Animal work provides further evi-
dencethatnatriureticpeptideshavearole
in cardiomyopathy prevention. Both
atrial natriuretic peptide and BNP bind to
the same receptor, the natriuretic peptide
receptor(NPR-A).Ananimalmodelusing
the NPR-A knockout mouse (Npr
/)
showsthatthesemicehaveelevatedblood
pressure and marked cardiac hypertro-
phy and ﬁbrosis at birth (18). The role of
NPR-A in inhibiting cardiac hypertrophy
seems to be even more important in the
presence of hypoxia (23). Gopinath et al.
(24) found that mRNA levels for the atrial
natriuretic peptide gene were signiﬁ-
cantly higher in left ventricular tissue
from neonates of diabetic mothers than
from those control mothers, followed by
an18-folddecreaseinmRNAfromthe1st
to the 28th neonatal day in comparison
with a ﬁvefold decrease in the control ne-
onates during the same time with no dif-
ference between the cohorts by day 28.
This model ﬁts with the regression in di-
abetic cardiomyopathy that is usually
seeninthepostnatalperiod.Inourearlier
work (9), we demonstrated changes in
cardiac function in the ﬁrst trimester in
the diabetic population, which pre-
ceded functional changes seen in the
third trimester. Cardiac hypertrophy in
the fetus, namely a thickened intraven-
tricularwall,couldimplyelevatedafter-
load, which may explain the high levels
of proBNP circulating as an antihyper-
trophic factor. ProBNP release may de-
crease but not prevent the development
of signiﬁcant fetal cardiomyopathy.
We are the ﬁrst group to look at TnT
in fetuses of type 1 diabetic pregnancies,
and we found increased levels in this
group. We also noted a relationship be-
tween increased TnT levels and increased
UAPI in pregnant women with poorly
controlled type 1 diabetes. The umbilical
arteryisabranchofthefetalaortaandisa
surrogate marker of blood pressure in the
fetal arterial circulation and thus a mea-
sureoffetalafterload.Diabeticvasculopa-
thy is known to affect decidual vascular
histology, causing ﬁbrinoid necrosis,
atherosis, and thrombosis, and signiﬁ-
cantlyhigherresistanceindexesarefound
in the uterine arcuate arteries classiﬁed as
vasculopathic (25). Troponin release
occurs in response to ischemia, and it is
possiblethatincreaseddownstreamresis-
tance due to placental vasculopathy
causes a degree of hypoxia that affects the
fetal myocardium. Pietryga et al. (26)
found a correlation between A1C and in-
creased fetal umbilical artery resistance in
those with known pregestational vascu-
lopathy, which could reﬂect diabetes-
induced placental microvascular disease.
Abnormal placentation may lead to
chronic intrauterine hypoxia, which
could affect fetal myocardial function,
making diabetic fetuses more susceptible
to an acute hypoxic insult (27,28).
These data suggest that maternal pre-
gestational type 1 diabetes is associated
with signiﬁcant effects on fetal cardiac
function with correlation between inter-
ventricular septal thickening and proBNP
release in diabetic pregnancy. Poor glyce-
mic control in early pregnancy may
change fetal cardiac gene activation and
predispose the fetus to myocardial hyper-
trophy, which explains why hypertrophy
can develop even in the presence of good
glycemic control later in pregnancy. The
BNP/NPR receptor pathway may thus be
involved in the third trimester cardiomy-
opathy so commonly seen in diabetic
pregnancy. Early pregnancy hyperglyce-
mia may also have an effect on the devel-
oping placenta and impaired placental
functioning may result in chronic intra-
uterinehypoxiacausingischemicdamage
to the fetal myocardium and thus TnT
release.
This article adds to the body of liter-
ature on diabetic cardiomyopathy and
our understanding of the pathways in-
volved. Because poor control in early
pregnancy is a recognized risk factor for
late intrauterine death, it is possible that
hyperglycemia-induced fetal program-
ming may lead to a susceptibility to
cardiomyopathy and “unexplained” in-
trauterine death. Further genomic and
proteomic studies of the effect of hyper-
glycemia and hyperinsulinemia on the
diabetic placenta and the developing
myocardium may provide more answers.
This article further emphasizes the need
for stringent glycemic control, both pre-
conceptually and in early pregnancy.
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